Ancora Biotech is a privately held company supporting the clinical development of three multi-specific antibodies.
Ancora Biotech has raised $60.0M in total funding. The most recent round was Series A. The last funding was announced in June 2022.
Ancora Biotech's investors include Lightspeed Venture Partners, SR One.
Ancora Biotech is headquartered in Palo Alto, United States.
Ancora Biotech is a privately held company supporting the clinical development of three multi-specific antibodies.
Ancora Biotech is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Ancora Biotech — Funding & Investors." VCBacked, June 9, 2022, https://www.vcbacked.co/company/ancora-biotech. Accessed November 16, 2026.
VCBacked. (2022). Ancora Biotech — Funding & Investors. Retrieved November 16, 2026, from https://www.vcbacked.co/company/ancora-biotech
{{cite web |title=Ancora Biotech — Funding & Investors |url=https://www.vcbacked.co/company/ancora-biotech |website=VCBacked |access-date=November 16, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at Ancora Biotech? Request a listing update